Plasma interleukin-23 and circulating IL-17A⁺IFNγ⁺ ex-Th17 cells predict opposing outcomes of anti-TNF therapy in rheumatoid arthritis.

ABSTRACT:

Objectives

TNF-α inhibitors are widely used in rheumatoid arthritis (RA) with varying success. Response to TNF-α inhibition may reflect the evolution of rheumatoid inflammation through fluctuating stages of TNF-α dependence. Our aim was to assess plasma concentrations of Th-17-related cytokines and the presence of circulating effector T-cells to identify predictors of response to TNF-α inhibitors.

Methods

Ninety-three people with RA were seen prior to and 4-6 months after commencing etanercept or adalimumab. Plasma concentrations of Th17-related cytokines, circulating effector T-cells, their production of relevant transcription factors and intracellular cytokines were measured at baseline. EULAR response criteria were used to define poor (ΔDAS28 ≤ 1.2 and/or DAS28 > 3.2) and

SUBMITTER: Millier MJ 

PROVIDER: S-EPMC8881822 | biostudies-literature | 2022 Feb

REPOSITORIES: biostudies-literature